Albireo Pharma (ALBO) is developing A4250 targeting a rare pediatric liver disease called Progressive familial intrahepatic cholestasis (PFIC), where bile formation is disrupted, leading to subsequent liver failure.
To be clear, the authority on Seeking Alpha for liver diseases is First Genesis Consulting, fellow Marketplace contributor and a trained academic hepatologist. A percentage of my understanding of ALBO comes from his work. However, his work on ALBO, in my very humble opinion, lacks in two aspects. One, his style is quite difficult for a layperson to understand, which is something I